toceranib-phosphate and Soft-Tissue-Neoplasms

toceranib-phosphate has been researched along with Soft-Tissue-Neoplasms* in 1 studies

Trials

1 trial(s) available for toceranib-phosphate and Soft-Tissue-Neoplasms

Article	Year
The tyrosine kinase inhibitor toceranib in feline injection site sarcoma: efficacy and side effects. Veterinary and comparative oncology, 2017, Volume: 15, Issue:2 Because of their locally invasive growth and high recurrence rate despite of aggressive local therapy, treatment of feline sarcomas is challenging. The tyrosine kinase inhibitor (TKI) toceranib is currently licensed for the treatment of canine mast cell tumours. There are only few reports about TKI usage in cats. Previous studies indicated promising potential of TKI for the treatment of feline injection site sarcoma (FISS). In this prospective clinical trial, 18 cats with unresectable FISS were treated at a target dosage of 3.25 mg kg Topics: Animals; Antineoplastic Agents; Cat Diseases; Cats; Female; Indoles; Injections; Male; Protein-Tyrosine Kinases; Pyrroles; Sarcoma; Soft Tissue Neoplasms	2017

Article

Year

The tyrosine kinase inhibitor toceranib in feline injection site sarcoma: efficacy and side effects.

Veterinary and comparative oncology, 2017, Volume: 15, Issue:2

Because of their locally invasive growth and high recurrence rate despite of aggressive local therapy, treatment of feline sarcomas is challenging. The tyrosine kinase inhibitor (TKI) toceranib is currently licensed for the treatment of canine mast cell tumours. There are only few reports about TKI usage in cats. Previous studies indicated promising potential of TKI for the treatment of feline injection site sarcoma (FISS). In this prospective clinical trial, 18 cats with unresectable FISS were treated at a target dosage of 3.25 mg kg

Topics: Animals; Antineoplastic Agents; Cat Diseases; Cats; Female; Indoles; Injections; Male; Protein-Tyrosine Kinases; Pyrroles; Sarcoma; Soft Tissue Neoplasms

2017